ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation

NASDAQ:ASTH • US03763A2078

Current stock price

31.5 USD
+0.9 (+2.94%)
At close:
31.5483 USD
+0.05 (+0.15%)
After Hours:

This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ASTH Profitability Analysis

1.1 Basic Checks

  • In the past year ASTH was profitable.
  • ASTH had a positive operating cash flow in the past year.
  • In the past 5 years ASTH has always been profitable.
  • ASTH had a positive operating cash flow in each of the past 5 years.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.01%, ASTH is in line with its industry, outperforming 51.00% of the companies in the same industry.
  • With a Return On Equity value of 2.89%, ASTH perfoms like the industry average, outperforming 57.00% of the companies in the same industry.
  • ASTH has a Return On Invested Capital (3.75%) which is in line with its industry peers.
  • ASTH had an Average Return On Invested Capital over the past 3 years of 5.51%. This is below the industry average of 8.51%.
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROIC 3.75%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With a Profit Margin value of 0.71%, ASTH perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ASTH has declined.
  • ASTH has a Operating Margin of 3.08%. This is comparable to the rest of the industry: ASTH outperforms 55.00% of its industry peers.
  • ASTH's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 10.73%, ASTH is doing worse than 73.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASTH Health Analysis

2.1 Basic Checks

  • ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • ASTH has more shares outstanding than it did 1 year ago.
  • ASTH has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.54. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASTH's Altman-Z score of 2.54 is in line compared to the rest of the industry. ASTH outperforms 59.00% of its industry peers.
  • ASTH has a debt to FCF ratio of 9.94. This is a negative value and a sign of low solvency as ASTH would need 9.94 years to pay back of all of its debts.
  • ASTH's Debt to FCF ratio of 9.94 is in line compared to the rest of the industry. ASTH outperforms 41.00% of its industry peers.
  • A Debt/Equity ratio of 1.27 is on the high side and indicates that ASTH has dependencies on debt financing.
  • ASTH's Debt to Equity ratio of 1.27 is on the low side compared to the rest of the industry. ASTH is outperformed by 66.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Altman-Z 2.54
ROIC/WACC0.46
WACC8.07%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • ASTH has a Current Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • ASTH has a Current ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 52.00% of its industry peers.
  • A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Quick ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 58.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ASTH Growth Analysis

3.1 Past

  • ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
  • ASTH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.74% yearly.
  • Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 56.39%.
  • Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 35.87% on average per year.
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%

3.2 Future

  • ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.34% yearly.
  • ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.59% yearly.
EPS Next Y173.72%
EPS Next 2Y104.54%
EPS Next 3Y69.85%
EPS Next 5Y54.34%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. ASTH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 68.48, which means the current valuation is very expensive for ASTH.
  • Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
  • ASTH is valuated expensively when we compare the Price/Earnings ratio to 27.87, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 25.02 indicates a quite expensive valuation of ASTH.
  • ASTH's Price/Forward Earnings ratio is in line with the industry average.
  • ASTH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.51.
Industry RankSector Rank
PE 68.48
Fwd PE 25.02
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ASTH is on the same level as its industry peers.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 74.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.91
EV/EBITDA 14.75
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ASTH's earnings are expected to grow with 69.85% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y104.54%
EPS Next 3Y69.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASTH Dividend Analysis

5.1 Amount

  • No dividends for ASTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTH Fundamentals: All Metrics, Ratios and Statistics

ASTRANA HEALTH INC

NASDAQ:ASTH (4/17/2026, 8:00:02 PM)

After market: 31.5483 +0.05 (+0.15%)

31.5

+0.9 (+2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners60.09%
Inst Owner ChangeN/A
Ins Owners9.93%
Ins Owner Change4.35%
Market Cap1.56B
Revenue(TTM)3.18B
Net Income(TTM)22.49M
Analysts84.71
Price Target36.72 (16.57%)
Short Float %7.47%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP35.06%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.4%
Min EPS beat(2)-97.78%
Max EPS beat(2)10.99%
EPS beat(4)1
Avg EPS beat(4)-44.97%
Min EPS beat(4)-97.78%
Max EPS beat(4)10.99%
EPS beat(8)4
Avg EPS beat(8)-50.25%
EPS beat(12)7
Avg EPS beat(12)-23.47%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.15%
Revenue beat(4)2
Avg Revenue beat(4)-1.11%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)0.57%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.78%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.93%
PT rev (3m)-4.42%
EPS NQ rev (1m)9.09%
EPS NQ rev (3m)28.83%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-1.24%
Revenue NQ rev (1m)1.08%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)0.05%
Valuation
Industry RankSector Rank
PE 68.48
Fwd PE 25.02
P/S 0.49
P/FCF 14.91
P/OCF 13.6
P/B 2
P/tB N/A
EV/EBITDA 14.75
EPS(TTM)0.46
EY1.46%
EPS(NY)1.26
Fwd EY4%
FCF(TTM)2.11
FCFY6.71%
OCF(TTM)2.32
OCFY7.35%
SpS64.32
BVpS15.75
TBVpS-7.22
PEG (NY)0.39
PEG (5Y)N/A
Graham Number12.7688 (-59.46%)
Profitability
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROCE 6.12%
ROIC 3.75%
ROICexc 5.12%
ROICexgc 160.26%
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
FCFM 3.28%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ROICexc(3y)8.45%
ROICexc(5y)10.18%
ROICexgc(3y)90.21%
ROICexgc(5y)71.8%
ROCE(3y)9%
ROCE(5y)10.61%
ROICexgc growth 3Y64.68%
ROICexgc growth 5Y30.22%
ROICexc growth 3Y-25.1%
ROICexc growth 5Y-14.45%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
F-Score4
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Debt/EBITDA 6.89
Cap/Depr 22.09%
Cap/Sales 0.32%
Interest Coverage 2.14
Cash Conversion 79.65%
Profit Quality 464.67%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.54
F-Score4
WACC8.07%
ROIC/WACC0.46
Cap/Depr(3y)70.53%
Cap/Depr(5y)90.42%
Cap/Sales(3y)0.92%
Cap/Sales(5y)1.45%
Profit Quality(3y)210.81%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
EPS Next Y173.72%
EPS Next 2Y104.54%
EPS Next 3Y69.85%
EPS Next 5Y54.34%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%
EBIT growth 1Y9.82%
EBIT growth 3Y-2%
EBIT growth 5Y4.04%
EBIT Next Year220.56%
EBIT Next 3Y59.52%
EBIT Next 5Y39.29%
FCF growth 1Y136.58%
FCF growth 3Y20.86%
FCF growth 5Y18.35%
OCF growth 1Y119.54%
OCF growth 3Y11.74%
OCF growth 5Y19.94%

ASTRANA HEALTH INC / ASTH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


Can you provide the profitability details for ASTRANA HEALTH INC?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for ASTH stock?

The Earnings per Share (EPS) of ASTRANA HEALTH INC (ASTH) is expected to grow by 173.72% in the next year.


Can you provide the dividend sustainability for ASTH stock?

The dividend rating of ASTRANA HEALTH INC (ASTH) is 0 / 10 and the dividend payout ratio is 35.06%.